AAN 2022 | Subjective cognitive decline as a preclinical phase of Alzheimer’s disease

Giulia Giacomucci, MD, University of Florence, Florence, Italy, explains subjective cognitive decline as a preclinical phase of neurodegenerative disease and discusses the factors which could influence the progression to mild cognitive impairment (MCI) and to Alzheimer’s disease (AD). Certain genetic factors that could be responsible have been investigated, including specific polymorphisms of the BDNF and CLOCK genes. Dr Giacomucci also discusses the development of biomarkers that could be used to assess cognitive decline. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.